KalVista Pharmaceuticals Inc [KALV] stock is trading at $11.32, down -1.57%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KALV shares have gain 3.28% over the last week, with a monthly amount drifted -19.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock has seen the most recent analyst activity on January 31, 2025, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $19. Previously, TD Cowen started tracking the stock with Buy rating on January 07, 2025, and set its price target to $30. On December 18, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $22 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $30 on June 15, 2020. SVB Leerink initiated its recommendation with a Outperform and recommended $31 as its price target on July 29, 2019. Needham started tracking with a Buy rating for this stock on March 20, 2019, and assigned it a price target of $35. In a note dated October 30, 2018, Jefferies initiated an Buy rating and provided a target price of $30 on this stock.
KalVista Pharmaceuticals Inc [KALV] stock has fluctuated between $7.30 and $17.28 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. KalVista Pharmaceuticals Inc [NASDAQ: KALV] shares were valued at $11.32 at the most recent close of the market. An investor can expect a potential return of 100.27% based on the average KALV price forecast.
Analyzing the KALV fundamentals
Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -142.21%, Pretax Profit Margin comes in at -138.53%, and Net Profit Margin reading is -142.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -1.96 and Total Capital is -1.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, KalVista Pharmaceuticals Inc’s Current Ratio is 5.37. Also, the Quick Ratio is 5.37, while the Cash Ratio stands at 3.24. Considering the valuation of this stock, the price to sales ratio is 399.94, the price to book ratio is 13.97.
Transactions by insiders
Recent insider trading involved Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER, that happened on Sep 08 ’25 when 7294.0 shares were sold. Chief Commercial Officer, Sweeny Nicole completed a deal on Aug 25 ’25 to sell 1480.0 shares. Meanwhile, CHIEF DEVELOPMENT OFFICER Yea Christopher sold 1954.0 shares on Aug 25 ’25.
